TP-252 / Thetis Pharma - LARVOL DELTA

Combination of Naproxen and a Chemically-Stable Eicosapentaenoic Acid Analogue Provide Additive Tumor Protection in Pirc rats. (PubMed, Int J Cancer) - "In this study, we determined whether the NSAID, naproxen, alone or in combination with a chemically-stable EPA analogue (TP-252), affects tumor formation in the Apc rat model. A comprehensive lipidomic analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers, including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were significantly correlated with tumor protection. Further studies with this drug combination should be focused on dose optimization and the role of EPA-derived lipid mediators in CRC initiation and progression."

Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Genetic Disorders • Oncology • Solid Tumor